G. Gunz

发表

Abnormal transduction mechanisms in pituitary adenomas.

A. Barlier, L. Caccavelli, A. Enjalbert, 1997, Hormone research.

The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies.

A. Barlier, P. Ruszniewski, A. Couvelard, 2006, European journal of endocrinology.

Somatostatin and Dopamine-Somatostatin Multiple Ligands Directed towards Somatostatin and Dopamine Receptors in Pituitary Adenomas

M. Culler, H. Dufour, A. Saveanu, 2006, Neuroendocrinology.

Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study.

M. Culler, G. Stalla, M. Theodoropoulou, 2008, Endocrine-related cancer.

The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society BIM-23244, a Somatostatin Receptor Subtype 2- and 5- Selective Analog with Enhanced Efficacy in Suppressing Growth Hormone (GH) from Octreotide-

P. Caron, M. Culler, L. Ouafik, 2022 .

A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies.

H. Dufour, A. Enjalbert, A. Saveanu, 2001, European journal of endocrinology.

Pronostic and Therapeutic Consequences of Gsα Mutations in Somatotroph Adenomas1

D. Figarella-Branger, A. Barlier, A. J. Zamora, 1998 .

Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity.

A. Barlier, A. J. Zamora, A. Enjalbert, 1999, The Journal of clinical endocrinology and metabolism.

Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.

J. Taylor, M. Culler, A. Barlier, 2002, The Journal of clinical endocrinology and metabolism.

Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.

M. Culler, A. Barlier, H. Dufour, 2008, European journal of endocrinology.

Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.

J. Taylor, M. Culler, H. Dufour, 2005, European journal of endocrinology.

BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.

J. Taylor, M. Culler, A. Barlier, 2005, Journal of endocrinological investigation.

Resistance to bromocriptine in prolactinomas.

F. Peillon, C. Jedynak, I. Pellegrini, 1989, The Journal of clinical endocrinology and metabolism.

Different pathways of secretion for glycosylated and nonglycosylated human prolactin.

I. Pellegrini, F. Grisoli, P. Jaquet, 1990, Endocrinology.

The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Quantitative and Functional Expression of Somatostatin Receptor Subtypes in Human Prolactinomas*

M. Culler, L. Ouafik, H. Dufour, 2022 .

Pit-1 gene expression in human lactotroph and somatotroph pituitary adenomas is correlated to D2 receptor gene expression.

D. Figarella-Branger, A. Barlier, A. Enjalbert, 1996, The Journal of clinical endocrinology and metabolism.

Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.

J. Bertherat, J. Epelbaum, T. Brue, 1992, The Journal of clinical endocrinology and metabolism.

Resistance to Bromocriptine in Prolactinomas

F. Peillon, C. Jedynak, I. Pellegrini, 1990 .

Direct action of opiates on bromocriptine-inhibited prolactin release by human prolactinoma cells in primary culture.

P. Giraud, E. Castanas, P. Jaquet, 1985, The Journal of clinical endocrinology and metabolism.

A new mutation of the gene encoding the transcription factor Pit-1 is responsible for combined pituitary hormone deficiency.

A. Barlier, P. Belicar, B. Vialettes, 1996, The Journal of clinical endocrinology and metabolism.

Pitx Factors Are Involved in Basal and Hormone-regulated Activity of the Human Prolactin Promoter*

M. Grino, M. Quentien, I. Pellegrini, 2002, The Journal of Biological Chemistry.

Regulation of prolactin, GH, and Pit-1 gene expression in anterior pituitary by Pitx2: An approach using Pitx2 mutants.

Marie Guillet, M. Quentien, I. Pellegrini, 2002, Endocrinology.

Expression of the members of the Ptx family of transcription factors in human pituitary adenomas.

D. Figarella-Branger, A. J. Zamora, M. Grino, 1999, The Journal of clinical endocrinology and metabolism.

Polymorphism of prolactin secreted by human prolactinoma cells: immunological, receptor binding, and biological properties of the glycosylated and nonglycosylated forms.

J. Peyrat, E. Fenouillet, I. Pellegrini, 1988, Endocrinology.

Polymorphism of thyrotropin and alpha subunit in human pituitary adenomas

G. Medri, C. Ronin, P. Jaquet, 1993, Journal of endocrinological investigation.

Macroprolactinemia revisited: a study on 106 patients.

T. Brue, A. Enjalbert, Adel I. Selim, 2002, The Journal of clinical endocrinology and metabolism.

Immunoradiometric analysis of circulating human glycosylated and nonglycosylated prolactin forms: spontaneous and stimulated secretions.

T. Hoffmann, I. Morange, T. Brue, 1992, The Journal of clinical endocrinology and metabolism.

Hormonal regulation of prolactin release by human prolactinoma cells cultured in serum-free conditions.

F. Grisoli, P. Jaquet, G. Gunz, 1985, Hormone Research.

A human pituitary adenoma secreting thyrotropin and prolactin: immunohistochemical, biochemical, and cell culture studies.

B. Weintraub, J. Hassoun, F. Grisoli, 1984, The Journal of clinical endocrinology and metabolism.

Prolactin isoforms secreted by human prolactinomas.

T. Hoffmann, T. Brue, C. Ronin, 1992, Hormone research.

Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas.

D. Figarella-Branger, A. Barlier, H. Dufour, 2008, Cancer research.

Resistance of Human Pituitary Adenomas Hormonal Hypersecretion and Reverses Octreotide Somatostatin Receptor sst 2 Decreases Cell Viability and

D. Figarella-Branger, A. Barlier, H. Dufour, 2008 .

Somatostatin Receptor sst 2 Decreases Cell Viability and Hormonal Hypersecretion and Reverses Octreotide Resistance of Human Pituitary Adenomas

D. Figarella-Branger, A. Barlier, H. Dufour, 2008 .

The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Human Somatostatin Receptor Subtypes in Acromegaly: Distinct Patterns of Messenger Ribonucleic Acid Expression and Hormone Suppression Identify

M. Culler, A. J. Zamora, L. Ouafik, 2022 .

Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas.

D. Figarella-Branger, A. Barlier, A. J. Zamora, 1998, The Journal of clinical endocrinology and metabolism.

Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.

D. Dewailly, I. Morange, T. Brue, 1992, The Journal of clinical endocrinology and metabolism.

Pit-1 gene expression in the human pituitary and pituitary adenomas.

D. Figarella-Branger, A. Barlier, I. Pellegrini, 1994, The Journal of clinical endocrinology and metabolism.

In vitro corticotropin-releasing hormone (CRH) stimulation of adrenocorticotropin release from corticotroph adenoma cells: effect of prolonged exposure to CRH and its interaction with cortisol.

C. Oliver, M. Grino, F. Grisoli, 1988, The Journal of clinical endocrinology and metabolism.

Bromocriptine effects on cultured human prolactin-producing pituitary adenomas: in vitro ultrastructural, morphometric, and immunoelectron microscopic studies.

J. Hassoun, F. Grisoli, B. Devictor, 1985, The Journal of clinical endocrinology and metabolism.

Involvement of the pituitary-specific transcription factor pit-1 in somatolactotrope cell growth and death: an approach using dominant-negative pit-1 mutants.

C. Roche, M. Quentien, J. Franc, 2006, Molecular endocrinology.

Enkephalins in human pheochromocytoma biosynthesis and secretion.

P. Giraud, E. Castanas, C. Oliver, 1982, European Heart Journal.

Combined pituitary hormone deficiency due to the F135C human Pit-1 (pituitary-specific factor 1) gene mutation: functional and structural correlates.

S. Radovick, T. Brue, A. Enjalbert, 2001, Molecular endocrinology.

The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies.

A. Barlier, P. Ruszniewski, A. Couvelard, 2006, European journal of endocrinology.